E1210 (APX001A) is primarily investigated for its antifungal properties, making it a potential candidate for treating invasive fungal infections. Its mechanism of action involves targeting fungal cell wall synthesis, which is crucial for the survival of fungal pathogens. This makes it particularly effective against drug-resistant strains, such as Candida auris and Aspergillus species, which are often challenging to treat with conventional antifungal agents. Clinical trials have explored its use in immunocompromised patients, including those undergoing chemotherapy or organ transplantation, who are at higher risk of fungal infections. Additionally, its oral bioavailability offers a significant advantage over many existing antifungal drugs that require intravenous administration, improving patient compliance and convenience. Research continues to evaluate its efficacy, safety, and potential as a broad-spectrum antifungal therapy.